

Biosimilars manufacturing excellence

Enhance biosimilarity using the same insulin in cell culture media as originators

Success in the biosimilar industry depends on two critical factors:

- Achieving true biosimilarity to reference products
- Managing production costs effectively avoiding batch failures


This is why high-quality animal-free raw materials, like Recombinant Insulin, are essential to reduce variability, minimize contamination risks, and ultimately generate cost savings by improving process efficiency while maintaining the highest standards of product quality.

Many originator manufacturers utilize Recombinant Insulin for efficient mAb production. By adopting the same insulin in their cell culture media formulations, biosimilar manufacturers can access the same advantages as originator producers and increase their chances to achieve biosimilarity.




Recombinant Insulin helps achieve improved manufacturing processes

Increased mAb yields



Recombinant Insulin supplementation to different cell culture media improves mAb production in CHO cells.

Reproducible mAb yield with different insulin batches



Recombinant Insulin from different manufacturing batches shows consistent performance when supplemented to different chemically defined media. CV indicates coefficient of variation across different batches.

Obtaining economic returns

Supplementation of Recombinant Insulin represents an advantageous economic investment that reduces monoclonal antibody production costs by significantly improving process productivity.

Decrease in mAb production costs

